Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Iris Energy Limited (IREN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Iris Energy LimitedTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Iris Energy Limited vs Recursion Pharmaceuticals Inc — how do they compare? Iris Energy Limited trades at $43.97 (market cap $14.20B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: Iris Energy Limited is far larger — about 7.8× Recursion Pharmaceuticals Inc's market cap, and Iris Energy Limited is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

IRENRXRX
Market Cap
$14.20B$1.81B
Sector
EnergyHealth
52-Week High
$76.41$6.79
52-Week Low
$17.73$2.84
Enterprise Value
$15.95B$1.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Iris Energy Limited

IREN stock trades at $43.17, up 11.44% today amid positive AI infrastructure news. The technical picture is neutral with resistance near $42. Fundamentally, the company shows strong revenue growth to $501M in 2025 and has secured $2.8B in new AI contracts, though it has missed recent EPS estimates and reports negative ROE and ROA. Analyst sentiment is bullish with a $84.43 price target.

Outlook is driven by AI cloud expansion but carries execution risks. The stock offers growth potential from its $4B revenue target, yet high valuations and recent earnings misses pose challenges. Investors should weigh contract momentum against profitability concerns and sector volatility.

Recursion Pharmaceuticals Inc

RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.

Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Iris Energy Limited

Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.

Read more on IREN

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX